
# UCI <sup>1</sup> Comprehensive Cancer Center

# Thoracic Disease-Oriented Team


**Clinical Research Treatment Flowchart** 

www.cancer.uci.edu





Exon 18



**EGFR Mutations** 

**1L** 

**2L** 

UCI 23-95 (HARMONi) Randomized Double Blind: AK112/Placebo + Pem + Carbo

Mechanism: Novel PD-1/VEGF bispecific antibody w/ Chemo Coord: Celest Ramirez Accrual: 0/10

January 2024

UCI Comprehensive Cancer Center



#### Stage 1A / Adjuvant




Pending Activation

UCI 22-59 (ADAURA) Randomized: Osimertinib or Placebo

> Mechanism: TKI Coord: Jenny Choe Accrual: 0/10





## ADVANCED/METASTATIC

**1L** 

UCI 23-66 (Boehringer Ingelheim) BI-1810631 Monotherapy

> Mechanism: TKI Cord: Keagan Buttigieg Accrual: 0/5

Exon 19

Exon 20

#### UCI 21-234 (AstraZeneca)

<u>Randomized: Arm 1: T-DXD(Trastuzumab Deruxtecan) or</u> <u>Arm 2: Cisplatin or Carbo + Pemetrexed + Pembrolizumab</u>

\*Treatment Naïve for palliative intent systemic therapy in locally advanced or metastatic disease.

\*Documented Her2 Exon 19 or 20 mutation

\*Tumor sample must be available for central testing from fresh or archival.


\*No Slot Required prior to consenting if mutation of HER2 is available.

Accrual: 1/10

HER2 MUTATIONS

2L

UCI Comprehensive Cancer Center



**KRAS MUTATIONS** 



**Pending Activation** 

Immunotherapy + Radiation

#### <u>NRG-LU007</u>


<u>Treatment: (Randomized) Group 1:</u> <u>Atezolizumab Alone. Group 2:</u> <u>Atezolizumab + Radiation</u>

Mechanism: Immunotherapy + Radiation Coord: Richard Chang Accrual: 1/5

#### UCI 23-178

Treatment: BL-B01D1 IV Mechanism: IP binding to EGFR/HER3, antibody fragments of IP bind to EGFR/HER3, Fc segment of (ADCC) Coord: TBA Accrual: 0/10

ADVANCED/METASTATIC





Pending Activation

# NTRK 1-3

**1L** 

**2L** 

#### <u>UCI 16-79 (TPX-0005)</u>

<u>Mechanism: TKI</u> Coord: Stephanie Fernandez Accrual: 16/27

UCI Comprehensive Cancer Center

January 2024

# All Comers







### ROR2


UCI 21-161 (BA3021 /BioAtla) BA3021 alone an in comb w/ Nivolumab

Mechanism: Antibody drug conjugate Coord: Celest Ramirez Accrual: 0/5

**1L** 

**2L** 

UCI AChao Family Comprehensive Cancer Center



13

**ROS1 Mutations** 





Pending Activation

## **Database & Repository**

UCI 21-238: Database & Repository of Asian female never smokers w/ low dose CT scan Screening Study

> Mechanism: D Coord: TBD Accrual: 0/100



#### Open





Pending Activation

# Advanced / Metastatic

**2L** 

**1L** 

UCI 23-148: CJRB-01 (oral) + Pembrolizumab

Mechanism: Live biotherapeutic product containing a novel strain belonging in the species *Leuconostoc mesenteroides* (*L. mesenteroides* + *Pembrolizumab* Coord: TBD Accrual: 0/6

# **Non-Treatment Studies**



UCI 21-233: Mecbotamab vedotin (BA3011) &

Nivolumab

Mechanism: Immunotherapy Coord: Jenny Choe Accrual: 1/10

